-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Ovarian cancer remains the leading cause of death for women worldwide, with approximately 313,959 cases of ovarian cancer and approximately 20,252 ovarian cancer-related deaths worldwide in 2020
.
Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications arise with repeated platinum therapy
ovarian cancer
This study (NRG-GY004) was designed to evaluate the efficacy of two all-oral non-platinum drugs olaparib or olaparib/cediranib versus platinum-based chemotherapy in ovarian cancer
.
The NRG-GY004 study is an open-label, randomized Phase 3 trial enrolling patients with definitively diagnosed high-grade serous or endometrioid platinum-sensitive ovarian cancer
.
The patients were randomized (1:1:1) into three groups to receive platinum-based chemotherapy, olaparib, and olaparib/cediranib, respectively
diagnosis
PFS of three groups of patients
PFS of three groups of patientsFrom February 04, 2016 to November 13, 2017, a total of 565 patients were randomized into three groups
.
The median progression-free survival was 10.
The median progression-free survival was 10.
PFS in patients with BRCA mutations
PFS in patients with BRCA mutationsAmong patients with germline BRCA mutations, the relative PFS hazard ratios were 0.
63 and 0.
55 for olaparib and olaparib/cediranib, respectively, compared with chemotherapy
.
Among patients without BRCA mutations, the relative PFS hazard ratios were 1.
Among patients with germline BRCA mutations, the relative PFS hazard ratios were 0.
In short, the olaparib/cediranib combination did not prolong progression-free survival in ovarian cancer patients compared with chemotherapy
.
However , in patients with BRCA germline mutations, both olaparib and olaparib/cediranib had significant clinical activity
Both olaparib and olaparib/cediranib had significant clinical activity in patients with BRCA germline mutations
Original source:
Joyce F.
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
